SEC Filings

Form 13F-HR OpenView Management, For: Jun 30 Aug 11, 2022 10:27AM .FormData { color: blue; background-color: white; font-size: small; font-family: Times, serif; } .FormDataC { color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center; } .FormDataR { color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align:... (continue reading...)

Form 6-K AEGON NV For: Jun 30 Aug 11, 2022 10:27AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

Form 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the six months ended June 30, 2022

Commission File Number 001-10882

Aegon N.V.

(Translation of registrant’s name into English)

Aegonplein 50

P.O. Box 85

2501 CB The Hague

The Netherlands

(Address of principal executive offices)

Indicate by check mark... (continue reading...)

Form SC 13D/A Pasithea Therapeutics Filed by: Camac Fund, LP Aug 11, 2022 10:27AM

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

Pasithea Therapeutics Corp.

 

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

 

(Title of Class of Securities)

 

70261F103

 

(CUSIP Number)

 

David Delaney

Concord Investment Partners Ltd.

60 St. Clair Avenue East, Suite 702

Toronto, ON, M4T 1N5

Canada

(416)... (continue reading...)

Form ABS-15G/A FEDERAL NATIONAL MORTGAG Aug 11, 2022 10:26AM http://archive.fast-edgar.com/20220811/AS2LV222H22289S2222R2Z42M3MWZ2225242 Filed on: August 11, 2022

Form 424B2 CITIGROUP INC Aug 11, 2022 10:26AM

The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, underlying supplement, prospectus supplement and prospectus are not an offer to sell these securities, nor are they soliciting an offer to buy these securities, in... (continue reading...)